A Phase 2 Study of REGN2810 a Fully Human Monoclonal Antibody to Programmed Death-1 in Patients with Advanced Basal Cell Carcinoma who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy or were Intolerant of Prior Hedgehog Pathway Inhibitor therapy

Brief description of study

If you have been diagnosed with advanced metastatic (cancer spreading to other areas within the body) basal cell carcinoma or unresectable advanced basal cell carcinoma and experienced disease progression while on hedgehog inhibitor (HHI) therapy; you may qualify to participate in a study evaluating how effective REGN2810 (an anti-PD-1 monoclonal antibody) is effective at preventing further progression of your disease.  This study will also evaluate the safety and tolerability of REGN2810 in your body, as well as the immune system's response to the drug.

Clinical Study Identifier: s17-00080
ClinicalTrials.gov Identifier: NCT03132636
Principal Investigator: Anna C Pavlick
Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.